Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. - Wikidata - awgldk - TriplyDB

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

http://www.wikidata.org/entity/Q37009001

about

Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.

P2860

Q38931460-9BE11530-D46E-4906-BEDC-407D0709FEA4 Q38956444-05071BA2-38BD-4318-B5AB-6BD657161625 Q41194522-CCF9EEEF-AB54-428A-9CDC-335F6FC31A12 Q47395532-054C658F-78B0-406E-8DAB-A1EFE462A8EE

P2860

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

http://www.wikidata.org/entity/Q37009001

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 May 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

@en

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

@nl

type

label

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

@en

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

@nl

prefLabel

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

@en

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

@nl

P1433

Q37009001-BE1E3BEE-56C8-4CC1-A6BF-901A91A6F251

P1476

Q37009001-5EB884B7-4B4E-40B0-AEC3-F5E9D170CE6D

P2093

Q37009001-01555773-4268-484D-B695-868714F25D07

Q37009001-111A3BAB-F382-43AE-856B-26B8EC670892

Q37009001-1CEC2415-A49B-4748-B6EF-1E9352CADEA5

Q37009001-21DBFE91-AC57-4D95-9EDC-8EE1E7BADCF3

Q37009001-2369CC57-C91C-42BC-87B8-DAD83495BFD4

Q37009001-2A8BA5FF-92C8-434C-BA47-21BB6455DF00

Q37009001-36A7E67F-F08E-4F05-9764-F64065D1B199

Q37009001-6587868B-F5B3-4E04-899E-25AA00895AD5

Q37009001-715C3EB8-6EC8-4470-8B63-A0CBF9C55192

Q37009001-715C8189-A437-4E9E-9597-407C8B155AC2

P2860

Q37009001-0E4447E9-1505-4685-A7FE-22C769CD668A

Q37009001-0F97589E-D274-4BFC-A891-041CD8927DF3

Q37009001-19C25AB1-F5D7-4F07-9497-34C8B59057EA

Q37009001-1BED79A7-EB3A-4A7B-981F-7819541925DA

Q37009001-236489C1-ECEF-4A1D-B301-F4B040B5EBAE

Q37009001-2E7B4136-6F07-42BE-876C-0A4848A38A49

Q37009001-30565759-4FE7-454E-A0F6-8A562962E88A

Q37009001-38AA997B-B3DE-40D9-9726-5EA1C996B1AB

Q37009001-3AC50C1A-BC61-4200-B86C-49C16BE5FAF5

Q37009001-40F5273B-920C-4683-B80A-AC0EF9E0859F

P304

Q37009001-B2D202C4-63E6-4D0F-8CC5-C569B3FD26D3

P31

Q37009001-ADC51E38-0CDD-4E29-AA25-2058F4B5A716

P356

Q37009001-21C57A86-1E16-4E1A-91AD-3B971B724FE9

P433

Q37009001-EFEB3591-DBFE-439E-B88A-1D794F2E912A

P478

Q37009001-B0701910-6C94-4349-93CC-8EA474840140

P50

Q37009001-A7154A50-EBB1-4DF1-A6C7-3C1C19C8BB7F

P577

Q37009001-079F73FC-350C-4300-8B69-D7FCDBCEFDCE

P698

Q37009001-3E38B8E6-E0B9-419B-BB08-1EE21D51AAFF

P932

Q37009001-692EB400-C04C-456A-8A14-347107851538

P356

P1433

P1476

Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

@en

P2093

Andreas M Heilmann

http://www.w3.org/2001/XMLSchema#string

Chaitali Nangia

http://www.w3.org/2001/XMLSchema#string

Doron Lipson

http://www.w3.org/2001/XMLSchema#string

Ishwaria Subbiah

http://www.w3.org/2001/XMLSchema#string

James X Sun

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Ross

http://www.w3.org/2001/XMLSchema#string

Jo-Anne Vergilio

http://www.w3.org/2001/XMLSchema#string

Julia A Elvin

http://www.w3.org/2001/XMLSchema#string

Kai Wang

http://www.w3.org/2001/XMLSchema#string

Manisha H Shah

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

RAS proto-oncogene in medullary thyroid carcinoma

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.

Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B

Cabozantinib in progressive medullary thyroid cancer.

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors.

P304

339-346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000445978

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P50

Juliann Chmielecki

P577

2016-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27207748

http://www.w3.org/2001/XMLSchema#string

P932

4909575

http://www.w3.org/2001/XMLSchema#string